IQVIA Holdings Inc. (NYSE:IQV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has received a consensus rating of “Moderate Buy” from the twenty-four research firms that are currently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $226.32.

IQV has been the subject of a number of research analyst reports. HSBC lowered shares of IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a research note on Monday, May 19th. UBS Group reduced their target price on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Finally, Hsbc Global Res lowered shares of IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th.

IQVIA Price Performance

Shares of IQV stock opened at $152.07 on Friday. IQVIA has a 12-month low of $134.65 and a 12-month high of $252.88. The firm has a market capitalization of $26.31 billion, a price-to-earnings ratio of 20.28, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a fifty day moving average of $147.69 and a 200-day moving average of $179.13.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the prior year, the business earned $2.54 EPS. On average, equities research analysts forecast that IQVIA will post 10.84 earnings per share for the current year.

Institutional Investors Weigh In On IQVIA

Institutional investors and hedge funds have recently modified their holdings of the company. American National Bank & Trust bought a new stake in shares of IQVIA in the 1st quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC raised its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 130 shares during the period. Synergy Asset Management LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $33,000. Finally, AllSquare Wealth Management LLC bought a new stake in shares of IQVIA in the 1st quarter valued at about $33,000. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.